We started commercial sales activity of the ArtVentive EOS™ in April 2016. From the very beginning, ArtVentive adopted a focused approach to the sales process, development and continuous growth. In the European markets, we market and sell our products through industry distributors. In the U.S, we market directly to selected University Hospitals and private clinics constantly expanding of customer base. We have targeted sales and marketing efforts to interventional radiologists and vascular surgeons with experience using similar catheter-based procedures, such as angioplasty and stenting. Peer-to-peer education is also a key element of our sales strategy.
Our progress to date has been significant where we have achieved 400 – 500% sales growth per quarter. Management is very confident in the sales development and our company’s expansion based on natural organic growth.
ArtVentive Medical Group, Inc. Files Form 15 with the Securities and Exchange Commission Focusing on Rapid Sales Growth Not Public Reporting
ArtVentive Medical Group, Inc. (“ArtVentive”) announced today that it filed a Form 15 with the Securities and Exchange Commission relieving it of all reporting requirements with the Securities and Exchange Commission.
ArtVentive Concludes Successful Clinical Demonstrations of the Revolutionary EOS™ Occlusion System at SIR 2017 in Washington DC.
The ArtVentive team conducted a series of very successful meetings and workshops at the conference with EOS™ which was featured in several prominent events held at the conference auditorium, the exhibition floor and at hands-on workshops.
EOS™ attracted considerable attention from the audience, primarily interventional radiologists from the US, Europe, Australia and Asia, because it is the only occlusion device that immediately, safely and accurately stops blood flow.
ArtVentive EOS™ Device featured at SIR 2017 Conference
Visit us at booth #560.
ArtVentive Medical Group, Inc. (“ArtVentive”) announced today its strategic sales plan for the company’s growth and highlighted recent commercialization progress in the United States and Europe.
Dr, Leon Rudakov, ArtVentive’s founder and Chief Technology Officer, and Bill Olson, newly appointed Chief Executive Officer, identified an innovative sales and marketing strategy for ArtVentive’s revolutionary blood vessel occlusion device EOS™.
ArtVentive Medical Group Inc. (“ArtVentive”) announced today that Mr. William Olson has joined as its Chief Executive Officer to execute a sales and marketing program to commercialize and distribute its revolutionary blood occlusion device.
Evaluation of Effectiveness of Embolization in Pelvic Congestion Syndrome with the New Vascular Occlusion Device (ArtVentive EOS™): Preliminary Results
Successful embolization procedures with ArtVentive EOS™. This study aimed to collect confirmatory data in support of the safety and efficiency of the ArtVentive EOS™ for the treatment of the pelvic congestion syndrome (PCS). A decrease in pelvic pain intensity based on the VAS was considered a clinical success.
ArtVentive Launches U.S. commercialization by Showcasing its EOS™ Device at GEST-2016. May 2016, New York
ArtVentive Medical Group, Inc. commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS™) at the Global Embolization Symposium and Technologies (GEST) in New York, NY on May 5-8. The introduction in the United States follows the initial commercialization in the E.U. last year.